Latest frontotemporal dementia Stories
(In response to Thursday evening's segment on frontotemporal degeneration on NBC's Nightly News with Brian Williams, AFTD releases this snapshot of another family dealing with FTD.) RALEIGH, N.C., June 14, 2013 /PRNewswire-USNewswire/ -- In the past six years, Arnette Lester of Raleigh, NC has lost all but a few of her teeth. She can no longer work or drive a car. Arnette has difficulty finding the right words and uses the same word to mean many different things; when she can't...
The most common genetic cause of both ALS (amyotrophic lateral sclerosis) and FTD (frontotemporal dementia) was recently identified as an alteration in the gene C9orf72. But how the mutation causes neurodegenerative disease appeared mysterious. Researchers at Emory University School of Medicine have demonstrated that this ALS/FTD mutation may be harmful because it creates an "RNA sponge," soaking up an important regulatory protein that binds RNA. The results were published online Monday...
Test to be unveiled at the American Academy of Neurology Annual Meeting in San Diego, March 16-23, 2013 MADISON, N.J. and WORCESTER, Mass., March 18, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced the availability of the first clinical test panel for aiding the diagnosis of suspected dementia due to treatable forms of cognitive impairment. The test panel is believed to be the first commercial...
Rosa Rademakers, Ph.D. and Bryan Traynor, M.D., Ph.D. Receive Essey Award WASHINGTON, March 12, 2013 /PRNewswire-USNewswire/ -- On Tuesday, March 19, The ALS Association and the American Academy of Neurology (AAN) will present the 2013 Sheila Essey Award for ALS Research at AAN's annual meeting in San Diego, California to Rosa Rademakers, Ph.D. and Bryan Traynor, M.D. Ph.D. These two scientists independently identified a mutation in the C9orf72 gene, on Chromosome 9, that causes ALS,...
Researchers at Mayo Clinic have discovered an abnormal protein that accumulates in the brains of many patients affected with two common neurodegenerative disorders — amyotrophic lateral sclerosis, also known as ALS or Lou Gehrig's disease, and frontotemporal dementia. They say their findings have uncovered a potentially new therapeutic target and biomarker that would allow clinicians to confirm diagnosis of the diseases. The study is published online today in the journal Neuron. The Mayo...
Neuron have discovered an abnormal protein that first forms as a result of genetic abnormalities and later builds up in the brains of many patients with either disease. "In identifying the novel protein that abnormally accumulates in the brains of affected patients, we have uncovered a potentially new therapeutic target and biomarker that would allow clinicians to confirm diagnosis of the diseases," says senior author Dr. Leonard Petrucelli, Chair of Neuroscience at Mayo Clinic in Florida....
WASHINGTON, Feb. 5, 2013 /PRNewswire/ -- Howard Fillit, MD, founding Executive Director and Chief Science Officer of the Alzheimer's Drug Discovery Foundation and George Vradenburg, Chairman of USAgainstAlzheimer's today issued a joint statement in response to an advisory opinion last week by the Medicare Evidence Development and Coverage Advisory Committee (MEDCAC) that there is insufficient evidence to support Medicare reimbursement for PET amyloid imaging scans in patients with...
WASHINGTON, Dec. 10, 2012 /PRNewswire-USNewswire/ -- Researchers supported by The ALS Association have discovered an important process that puts neurons at risk of the cell death, which characterizes numerous neurodegenerative diseases. The discovery, which was published today in the Proceedings of the National Academy of Sciences, highlights the links between several proteins known to go awry in ALS and a related disease, frontotemporal dementia (FTD). ALS is a progressive...
MANCHESTER, England, September 10, 2012 /PRNewswire/ -- Investigational drug study follows earlier study with promising results in mild to moderate Alzheimer's patients TauRx Therapeutics today announced the initiation of a global Phase 3 clinical trial in a type of Frontotemporal Dementia (FTD) also known as Pick's Disease. The announcement, which immediately follows The 8th International Conference on Frontotemporal Dementias, held...
(Ivanhoe Newswire) - 5.4 million Americans suffer from Alzheimers and 3 million from Parkinson's disease. Doctors who treat patients with these among other neurodegenerative conditions believe that the diseases are spreading though their patients' brains. The stages of both Alzheimers and Parkinson's disease show these pathological effects. Until recently, only in prion disease had this spread been shown, resulting in proof that the agent of spread is the prion protein. More recently,...
